Clinical Trials Contact

About this Clinical Trial

An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and Downbeat Nystagmus

All fields are required. *

Preferred contact method*

Thank you for your message about An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and Downbeat Nystagmus. You must verify your email address to receive further communication about this trial. Please check your email for a verification message.


Continue to explore Clinical Trials

Didn't receive an email verification message? You can wait a few minutes or submit another form.

Submit another form

We were not able to send your contact info at this time.

Continue to explore Clinical Trials

We're sorry, your verification code has expired. Please submit another form using the button below to receive communications about your preferred clinical trial study.

Submit a new form

Clinical Trial Study Email Verified An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and Downbeat Nystagmus

Continue to explore Clinical Trials